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Abstract: Objective:  Cartilage health is maintained in response to a range of mechanical stimuli
including compressive, shear and tensile strains and associated alterations in
osmolality. The osmotic-sensitive ion channel Transient Receptor Potential Vanilloid 4
(TRPV4) is required for mechanotransduction. Mechanical stimuli inhibit interleukin-1β
(IL-1β) mediated inflammatory signalling, however the mechanism is unclear. This
study aims to clarify the role of TRPV4 in this response. 
Design:  TRPV4 activity was modulated (GSK205 antagonist or GSK1016790A
(GSK101) agonist) in articular chondrocytes and cartilage explants in the presence or
absence of IL-1β, mechanical (10% cyclic tensile strain (CTS), 0.33Hz, 24hrs) or
osmotic loading (200mOsm, 24hrs).  Nitric oxide (NO), prostaglandin E  2  (PGE  2  )
and sulphated glycosaminoglycan (sGAG) release and cartilage biomechanics were
analysed. Alterations in post-translational tubulin modifications and primary cilia length
regulation were examined.
Results  : In isolated chondrocytes, mechanical loading inhibited IL-1β mediated NO
and PGE  2  release. This response was inhibited by GSK205. Similarly, osmotic
loading was anti-inflammatory in cells and explants, this response was abrogated by
TRPV4 inhibition. In explants, GSK101 inhibited IL-1β mediated NO release and
prevented cartilage degradation and loss of mechanical properties. Upon activation,
TRPV4 cilia localisation was increased resulting in HDAC6-dependent modulation of
soluble tubulin and altered cilia length regulation.
Conclusion:  Mechanical, osmotic or pharmaceutical activation of TRPV4 regulates
HDAC6-dependent modulation of ciliary tubulin and is anti-inflammatory. This study
reveals for the first time, the potential of TRPV4 manipulation as a novel therapeutic
mechanism to supress pro-inflammatory signalling and cartilage degradation.
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Tuesday, 04 August 2020 
Re: Article resubmission OAC10500  
To Joel A Block, 
We would like to thank both yourself and the reviewers once again for their careful review of our 
research article and the constructive feedback they have provided.  We have edited the manuscript 
for clarity and compliance with the word count, included further experimental detail in the methods 
section and made the corrections identified by reviewer 2.  
As discussed via email, we have been unable to incorporate the suggested experimental validation of 
the TRPV4 antagonist/agonist used in this study within the required timeframe due to the current 
COVID situation and issues with lab access for our research staff.  While we accept these data would 
add further rigor to our study, it is not expected to change our overall conclusions. The discussion 
section of the manuscript has been amended to acknowledge this and highlight numerous published 
studies validating the efficacy of these compounds in chondrocytes.  
We hope that with these additional changes you will support publication of this article in 
Osteoarthritis & Cartilage. 
 










1. Although the authors describe that to clarify TRPV4 activation and inactivation by GSK101 and 
GSK205 is not necessary because these methods using the agonist and antagonist are well 
established in multiple cell types including chondrocytes, all figures in this paper are based on 
the activation and inactivation of TRPV4 by using GSK101 and GSK205, respectively.  Therefore, 
the authors must show TRPV4 activation and inactivation by GSK101 and GSK205 as positive and 
negative control, respectively, using your isolated chondrocytes and cartilage implant. 
 
Response: 
Reviewer 2 has asked that we conduct a Ca2+ signalling analysis of isolated chondrocytes and 
cartilage explants in the presence of the TRPV4 agonist GSK1016790A (GSK101) and the 
antagonist (GSK205) in order to confirm the efficacy of these compounds in modulating channel 
activity in our hands.  
Although our study does not demonstrate the efficacy of these compounds we do provide 
evidence that they are able to modulate the process of mechanotransduction which is itself 
dependent on TRPV4 Ca2+ channel activity (O'Conor, Leddy et al. 2014). While we accept that 
confirmation of the efficacy of the TRPV4 agonists/antagonists will add to the rigor of this study 
however the addition of this data would not change our overall conclusions as significant work 
demonstrating their specificity/efficacy has been conducted previously (see references below).  
 
The experiments suggested are quite extensive to optimise and then conduct in both isolated 
cells and cartilage explants. Unfortunately we are unable to perform them in the timeframe 
offered due to the current covid situation and associated issues with lab access for the 
researchers on this study. Therefore we have added the additional statement below to the 
discussion to highlight that GSK205 and GSK101 modulation of Ca2+ signalling has not been 
analysed in this study but has been shown in numerous previous studies in chondrocytes. 
 
Line 344: 
‘…Previous studies demonstrate that GSK101 activates Ca2+ signalling in isolated chondrocytes 
[17, 48, 56], while GSK205 inhibits this response and blocks Ca2+ signalling in response to 
mechanical or osmotic loading [18, 57, 58]. While Ca2+ signalling was not assessed in the current 
study, we hypothesise that elevated Ca2+ levels may regulate HDAC activity…’ 
 
Extensive evidence in the literature confirming the efficacy of GSK205 and GSK101 in 
chondrocytes as used in the present study: 
 
• Demonstrated that 10 µM GSK205 inhibits ligand-gated activation of TRPV4 by ruthenium 
red or the TRPV4 agonist TRPV4 agonist 4αPDD in porcine articular chondrocytes (Phan, 
Leddy et al. 2009). 
• Demonstrated activation with 5nM GSK101  by patch clamp electrophysiology could be 
diminished by 5 µM GSK205 inhibitor in porcine articular chondrocytes (Kanju, Chen et al. 
2016). 
• Demonstrated that in healthy human chondrocytes and chondrocytes isolated from 
patients with metatropic dysplasia 1 µM GSK1016790A activated Ca2+ signalling which 
could be blocked by 50 µM GSK205 (Hurd, Kirwin et al. 2015). 
• Demonstrated 100nM GSK101 activated Ca2+ signalling in isolate murine chondrocytes 
(Servin-Vences, Moroni et al. 2017). 
• Demonstrated that 1 nM GSK101 or osmotic loading activated Ca2+ signalling which could 
be inhibited by 10 µM GSK205 in porcine articular chondrocytes (O'Conor, Leddy et al. 
2014). 
Detailed Response to Reviewers
 
 
2. There is no explain in Fig. 2D.   
Response: 
The figure legend for Fig.2D reads:  
‘(D) confocal microscopy of explants stained with Calcein-AM (live cells, green) and ethidium 
homodimer (dead cells, red).’ 
 
We have edited the manuscript for clarity, line 188 now reads: 
‘Chondrocyte viability was maintained throughout the experiment as determined by live/dead 
staining.’  
 
Furthermore, we have added further details of this analysis to the methods section, line 88: 
‘For live imaging, cell viability was assessed by live/dead staining at the end of the experimental 
period. Explants were incubated for 45 min at 37°C with 5 μM Ethidium homodimer‐1 (EthD‐1) to 
label dead cells and 5 μM Calcein AM, a marker for live cells.’ 
 
 
3. Line 189 Fig. 3D ------- > Fig. 2D Is it OK? 
Response: 
We apologise for this error, we have altered the text to the correct figure reference. 
 
4. Fig. 3B:  GSK205 ------ > GSK101  Is it OK? 
Response: 
We apologise for this error, this has been corrected in the new figure. 
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Abstract 
Objective: Cartilage health is maintained in response to a range of mechanical stimuli including 
compressive, shear and tensile strains and associated alterations in osmolality. The osmotic-sensitive 
ion channel Transient Receptor Potential Vanilloid 4 (TRPV4) is required for mechanotransduction. 
Mechanical stimuli inhibit interleukin-1β (IL-1β) mediated inflammatory signalling, however the 
mechanism is unclear. This study aims to clarify the role of TRPV4 in this response.   
Design: TRPV4 activity was modulated (GSK205 antagonist or GSK1016790A (GSK101) agonist) in 
articular chondrocytes and cartilage explants in the presence or absence of IL-1β, mechanical (10% 
cyclic tensile strain (CTS), 0.33Hz, 24hrs) or osmotic loading (200mOsm, 24hrs).  Nitric oxide (NO), 
prostaglandin E2 (PGE2) and sulphated glycosaminoglycan (sGAG) release and cartilage biomechanics 
were analysed. Alterations in post-translational tubulin modifications and primary cilia length 
regulation were examined.  
Results: In isolated chondrocytes, mechanical loading inhibited IL-1β mediated NO and PGE2 release. 
This response was inhibited by GSK205. Similarly, osmotic loading was anti-inflammatory in cells and 
explants, this response was abrogated by TRPV4 inhibition. In explants, GSK101 inhibited IL-1β 
mediated NO release and prevented cartilage degradation and loss of mechanical properties. Upon 
Title Page & Abstract
activation, TRPV4 cilia localisation was increased resulting in HDAC6-dependent modulation of 
soluble tubulin and altered cilia length regulation. 
Conclusion: Mechanical, osmotic or pharmaceutical activation of TRPV4 regulates HDAC6-dependent 
modulation of ciliary tubulin and is anti-inflammatory. This study reveals for the first time, the 
potential of TRPV4 manipulation as a novel therapeutic mechanism to supress pro-inflammatory 
signalling and cartilage degradation. 
Key words 
Cartilage, IL-1β, TRPV4, mechanotransduction, mechanobiology, hypo-osmolarity, cilia 
Running headline 
TRPV4 activation suppresses inflammation 
 
 
Introduction  1 
Osteoarthritis (OA) effects over 4.4 million people in the UK alone representing significant 2 
economic cost [1]. Cartilage health is maintained in response to mechanical stimuli, articular 3 
cartilage is routinely exposed to a wide array of dynamic mechanical loading consisting of 4 
compressive, shear and tensile strains as well as associated alterations in fluid shear and 5 
osmolality [2]. Mechanical loading in the form of compression or tensile strain is anti-6 
inflammatory in chondrocytes and blocks the release of the pro-inflammatory mediator’s 7 
nitric oxide (NO) and prostaglandin E2 (PGE2) in response to interleukin-1β (IL-1β) [3-5]. 8 
Inflammatory signalling contributes to cartilage degradation in OA thus understanding the 9 
link between mechanical loading and inflammation will have significant therapeutic impact. 10 
The osmotic-sensitive Ca2+ ion channel Transient Receptor Potential Vanilloid 4 (TRPV4) is 11 
highly expressed in articular chondrocytes and is activated by mechanical stimuli  [6, 7]. 12 
TRPV4 is required for mechanotransduction in chondrocytes and other cells types [7-9]. It 13 
mediates the regulation of pro-anabolic and anti-catabolic genes promoting matrix 14 
production and accumulation in agarose-embedded chondrocytes [7, 9]. TRPV4 mutations 15 
result in human skeletal dysplasia suggesting a role in bone development (for review see 16 
[10]). Indeed, chondrocytes from TRPV4-/- mice exhibit loss of osmosensitivity accompanied 17 
by joint degeneration indicating a central role for this channel protein in maintaining joint 18 
homeostasis [11, 12]. Pharmaceutical activation of TRPV4 inhibits NO release in response 19 
to inflammatory cytokines suggesting a potential mechanistic role in the anti-inflammatory 20 
effects of mechanical loading  [13, 14]. However, in apparent contradiction of these findings 21 
TRPV4 inhibition exerts an anti-inflammatory effect in the cardiovascular system, lung and 22 
peripheral nervous system [15-17]. This study therefore aims to clarify the regulatory role of 23 
TRPV4 in cartilage inflammatory signalling.   24 
TRPV4 localises to the plasma membrane and primary cilium, a small microtubule based 25 
signalling compartment present at the cell surface [18, 19]. Primary cilia have been 26 
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implicated in both chondrocyte mechanotransduction [20-22] and inflammatory signalling 27 
[23-26]. The cytoplasmic tubulin deacetylase histone deacetylase 6 (HDAC6) is enriched 28 
within the cilium and modulates cilia resorption through de-acetylation and polymerization of 29 
ciliary tubulin [27-29]. Post translational modification of ciliary tubulin influences intraflagellar 30 
transport (IFT), the microtubule based motility present within the cilium required for cilia-31 
mediated signalling [30, 31]. Previously we report that mechanical loading counteracts 32 
inflammatory signalling in response to the pro-inflammatory cytokine interleukin 1β (IL-1β) 33 
via HDAC6 activation in association with alterations in IFT/cilia [5]. A role for TRPV4 in this 34 
pathway has not previously been identified. 35 
In the present study, we demonstrate for the first time that TRPV4 activation by cyclic tensile 36 
strain, hypo-osmotic challenge or the TRPV4 agonist GSK1016790A inhibits pro-37 
inflammatory IL-1β signalling and cartilage degradation associated with alterations in primary 38 
cilia elongation. TRPV4 may therefore provide a novel target for the treatment of joint 39 
disease and other inflammatory pathologies. 40 
Methods 41 
Antibodies and reagents 42 
Chondrocytes were treated with interleukin-1β (IL-1β, 200-01B; Peprotech, London, UK), 43 
TRPV4 antagonist GSK205 (616522; Merck Millipore, London, UK) and agonist 44 
GSK1016790A (GSK101, G0798; Sigma Aldrich, Poole, UK). Antibodies for 45 
immunocytochemistry: acetylated α-tubulin (1:2000, T7451, Sigma Aldrich, Poole, UK) and 46 
TRPV4 (1:200, SAB2104243, Sigma Aldrich). Nuclei were counterstained with 4′,6-47 
diamidino-2-phenylindole  (DAPI, Sigma Aldrich). Antibodies for western blotting: acetylated 48 
α-tubulin (1:1000, T7451, Sigma Aldrich) and α-tubulin (1:1000, ab4074, Abcam, Cambridge, 49 
UK). 50 
Cartilage explant and chondrocyte culture  51 
Bovine cartilage explants and chondrocytes were obtained from 16 month steers as 52 
previously described [28]. Full depth articular cartilage was removed from the proximal 53 
surface of the metacarpal phalangeal joint and chondrocytes isolated by enzymatic 54 
digestion. Explants were harvested using a 5 mm diameter biopsy punch (BP-50F, Selles 55 
Medical Ltd, UK).  Both were cultured at 37 °C, 5% CO2 in Dulbeccos Minimal Essential 56 
Medial (DMEM, D5921, Sigma-Aldrich, Poole, UK) supplemented with 10% (v/v) foetal calf 57 
serum (FCS, F7524, Gibco, Paisley, UK), 1.9 mM L-glutamine (G7513), 96 U/ml penicillin 58 
(P4333, All Sigma-Aldrich, Poole, UK). Explants were rested for 2 d prior to experimentation 59 
while isolated chondrocytes were cultured to confluence. 60 
Application of cyclic tensile strain 61 
Isolated chondrocytes were cultured on collagen coated flexible elastomeric membranes and 62 
subjected to uniform, equibiaxial cyclic tensile strain (CTS) applied using the Flexcell 5000T 63 
system (Dunn Labortechnik GMbH).Cells were subjected to 0-10% strain for 24 h at 0.33 Hz.  64 
Application of osmotic loading 65 
Isolated cells were cultured for 24 h without serum in osmotically adjusted media at 200, 315 66 
or 400 mOsm, hereafter referred as hypo-, iso- or hyper- osmotic media respectively. 67 
Explants were cultured for up to 12 d under similar conditions with the addition of serum to 68 
maintain chondrocyte viability resulting in a slightly higher osmolarity of 318 mOsm for the 69 
iso-osmotic media. The osmolarity of all solutions was adjusted by adding D-mannitol 70 
(M4125, Sigma-Aldrich) or distilled water and measured using a freezing point depression 71 
osmometer.  72 
Biochemical analysis of NO, PGE2 and sGAG release 73 
Nitric Oxide (NO) release was assessed using the Griess assay based on quantification of 74 
nitrite (NO2), the stable product of NO degradation. Nitrite content was quantified against a 75 
sodium nitrite standard curve using the Galaxy Fluorstar spectrophotometer (BMG Labtech, 76 
UK). An immunoassay kit (KGE004B, R&D Systems, UK) was used to quantify PGE2 77 
concentrations in the media according to the manufacturer’s instructions. Results were 78 
corrected for non-specific binding and calibrated using a PGE2 standard curve. The release 79 
of sGAG into the culture media was quantified using the dimethylmethyleneblue (DMMB) 80 
assay against a chondroitin sulphate standard curve (6-sulphate:4-sulphate; 0.33:1; Sigma–81 
Aldrich).  82 
Immunocytochemistry, live imaging and confocal microscopy 83 
For immunocytochemistry, samples were fixed with 4% paraformaldehyde for 10 min, 84 
permeabilised for 5 min with 0.5% triton-X100/phosphate buffered saline (PBS) then blocked 85 
with 5% goat serum/PBS for 1 h. Primary antibody was incubated at 4°C overnight followed 86 
by appropriate Alexa Fluor conjugated secondary antibodies (Molecular Probes) for 1 h at 87 
room temperature. Cells were counterstained with 1 µg/ml DAPI for 5 min. For live imaging, 88 
cell viability was assessed by live/dead staining. Explants were incubated for 30 min with 5 89 
µM Calcein AM and 5 µM Ethidium homodimer-1 (EthD-1) prepared in appropriate osmotic 90 
adjusted media, washed and immediately imaged. Samples were imaged using a Zeiss 710 91 
ELYRA PS.1 microscope. For cilia analysis, samples were imaged using an x63/1.4 NA 92 
objective to generate confocal z-sections made throughout the cell depth (approximately 20 93 
sections) using 0.25 μm step size with an image format of 1024 x 1024 yielding a pixel size 94 
of 0.13 x 0.13 μm (image size approximately 135 x 135 μm). Cilia length and prevalence was 95 
quantified from resulting maximum projection images using Image J software (National 96 
Institutes of Health, Maryland, USA).  97 
Western blotting 98 
Cells were lysed in RIPA buffer (R0278, Sigma Aldrich) and total protein quantified by 99 
Bicinchoninic acid (BCA) assay. For the fractionation of soluble and polymerized tubulin, 100 
extraction buffer A (137 mM NaCl, 20 mM Tris-HCl, 1% Triton X-100, and 10% glycerol) was 101 
added to cells at 4 °C for 3 min, plates were gently swirled and the buffer removed and 102 
saved as the soluble tubulin  fraction. Immediately after, extraction buffer B (buffer A + 1% 103 
SDS) was added for 1 min, the remaining sample was scraped, incubated on ice for 30 min 104 
and saved as the polymerized  tubulin fraction. 105 
SDS–PAGE was performed under reducing conditions and proteins transferred to 106 
nitrocellulose membranes. Membranes were blocked in odyssey blocking buffer (Li-Cor 107 
Cambridge, UK) prior to overnight incubation with primary antibodies and infrared secondary 108 
antibodies (Li-Cor). Proteins were visualized using the Li-Cor Odyssey and quantified using 109 
Image Studio Lite software (Li-Cor). 110 
HDAC6 activity measurement 111 
A commercial fluorometric assay kit (K466-100, Biovision) was used to measure HDAC6 112 
activity according to the manufacturer’s instructions. This assay determines enzyme activity 113 
by exploiting the selectivity of tubacin for HDAC6 in combination with a fluorescent synthetic 114 
acetylated-peptide substrate. Cultures were lysed, a 10 µl aliquot was mixed with either 115 
acetylated substrate (sample) or with 2 μM tubacin and acetylated substrate (inhibitor 116 
control) then incubated for 30 min at 37°C. The deacetylase-dependent release of a 7-117 
amino-4-trifluoromethylcoumarin fluorophore (excitation/emission at 350/490 nm) was then 118 
measured on a Galaxy Fluorstar spectrophotometer (BMG Labtech, UK) and HDAC6 activity 119 
calculated as [sample-inhibitor control]. 120 
Mechanical testing of cartilage explants 121 
The mechanical behaviour of individual cartilage explants was measured using an MTS, 122 
Bionix 100. A 2 mm diameter core was cut from the centre of each 5 mm diameter cartilage 123 
explant and a tare load of 0.01 N applied to each explant which was then hydrated in culture 124 
media. The explants were subjected to a 20% uniaxial unconfined compressive strain (20% 125 
/min). This was followed by a stress relaxation period at constant 20% strain in which the 126 
load was recorded for a further 300 s. The load was recorded throughout the test at a 127 
sampling frequency of 60 Hz.  Stress–strain and stress–time curves were generated for each 128 
specimen and the following mechanical properties of the cartilage determined: 129 












The relaxation half-life was calculated as the time from the start of the relaxation phase until 133 
stress reduced to half the peak value. 134 
Statistical analyses 135 
The sample size for each experiment was chosen based on previous studies [5, 32] where 136 
analysis of cartilage degradation by biochemistry, immunohistochemistry and mechanical 137 
testing demonstrated that  6-8 samples/group is sufficient to detect a 25% difference in 138 
cartilage matrix catabolism at 80% power and a significance of p<0.05. Data analysis was 139 
conducted using GraphPad Prism version 8 (GraphPad software, La Jolla California USA, 140 
www.graphpad.com). Normality testing (Kolmogorov Smirnov test) was performed to confirm 141 
that data exhibited Gaussian distribution. For data sets that were not normally distributed, 142 
namely cilia length data, Box Cox transformation (λ=0.5) was performed prior to statistical 143 
analyses. Statistical significance was determined by T-Test, One-way, Two-way or Three-144 
way ANOVA as appropriate with post-hoc Tukey’s multiple comparisons performed to 145 
identify significant differences between groups. Statistically significant differences were 146 
determined based on a threshold of *= p<0.05, **=p<0.01 and ***=p=0.001. Data is 147 
presented as mean ± standard deviation (SD) unless otherwise stated.  148 
Results 149 
TRPV4 activation is required for the anti-inflammatory effects of mechanical loading 150 
in isolated chondrocytes 151 
IL-1β treatment (24 h) resulted in significant, dose-dependent release of NO and PGE2 (Fig. 152 
1AB, S1AB). In response to 1 ng/ml IL-1β isolated chondrocytes exhibited a 3.04-fold 153 
increase in nitrite levels indicative of NO release (Fig. 1A), and a 4.84-fold increase in PGE2 154 
release (Fig. 1B) which increased to 11.48- and 7.37-fold respectively in response to 10 155 
ng/ml IL-1β (Fig. S1A-B). Consistent with previous studies [5] this response was significantly 156 
reduced by mechanical loading in the form of CTS. IL-1β induced NO release was abolished 157 
by CTS such that there was no statistically significant effect at either 1 or 10 ng/ml (Fig. 1A, 158 
S1A). PGE2 release was completely inhibited by CTS at 1 ng/ml IL-1β (Fig. 1B) but only 159 
partially suppressed at 10 ng/ml (Fig. S1B).  160 
Simultaneous treatment with the TRPV4 antagonist GSK205 (10 µM) abolished the anti-161 
inflammatory effects of mechanical loading (Figure 1, S1). While GSK205 had no effect on 162 
NO or PGE2 release in unloaded cells with or without IL-1β, in loaded cells the IL-1β 163 
response was restored such that NO (Fig. 1A and S1A) and PGE2 release (Fig. 1B, S1B) 164 
were significantly increased by IL-1β. Neither IL-1β nor GSK205 treatment in the presence 165 
or absence of CTS influenced TRPV4 protein levels (Fig. S10). These data indicate the anti-166 
inflammatory effects of mechanical loading are mediated by TRPV4 activation. 167 
TRPV4 activation is required for the anti-inflammatory effects of hypo-osmotic loading 168 
in isolated chondrocytes and cartilage explants 169 
Isolated chondrocytes were treated with hyper-osmotic media (400 mOsm), hypo-osmotic 170 
(200 mOsm) or iso-osmotic media (315 mOsm) for 24 h (Figure 2AB, S2). Hyper-osmotic 171 
challenge had no significant effect on NO release, with or without IL-1β relative to the iso-172 
osmotic control (Fig. S2, S3). By contrast, hypo-osmotic challenge significantly attenuated 173 
the pro-inflammatory response to IL-1β (1 ng/ml), such that the increase in NO release at 24 174 
h was significantly reduced (p<0.001, Fig. 2A S2A). Hypo-osmotic challenge had no 175 
apparent effect on cell viability compared to control conditions based on brightfield 176 
microscopy (Figure 2B). In the presence of GSK205, the anti-inflammatory effect of hypo-177 
osmotic challenge on IL-1β induced NO release was completely inhibited by GSK205 such 178 
that the induction of NO release was not significantly different to control conditions (Fig. 2A). 179 
In the absence of IL-1β, GSK205 also had no effect on baseline NO or PGE2 levels (Fig. 180 
S2). 181 
In cartilage explants, hypo-osmotic challenge significantly reduced IL-1β induced NO release 182 
(Fig. 2C, p<0.001) such that there was no significant difference between IL-1β treated and 183 
untreated explants (Fig. 2C, S4A). In line with these findings hypo-osmotic challenge 184 
blocked the IL-1β mediated release of sGAG into the media, indicative of a reduction in 185 
extracellular matrix degradation (Fig. S4B). Chondrocyte viability was maintained throughout 186 
the experiment as determined by live/dead staining (Fig. 2D). Consistent with isolated cells, 187 
hyper-osmotic challenge (400 mOsm, 12 d) had no effect on NO or sGAG release in the 188 
presence or absence of 1 ng/ml IL-1β (Fig. S4). GSK205 treatment restored IL-1β-induced 189 
NO release in hypo-osmotic media (Fig. 2C) thus blocking the anti-inflammatory effect of 190 
osmotic challenge. Interestingly, GSK205 further increased IL-1β-induced NO release in iso-191 
osmotic, control media a response not seen in isolated cells (Fig. 2C). Together these data 192 
indicate the anti-inflammatory effects of hypo-osmotic loading are also mediated by TRPV4 193 
activation. 194 
TRPV4 activation is associated with altered primary cilia localisation and regulates 195 
cilia length  196 
IL-1β induces primary cilia elongation in articular chondrocytes and mediates downstream 197 
catabolic NF-κB signalling through regulation of IFT [5, 23, 24]. We therefore examined the 198 
involvement of primary cilia in the anti-inflammatory mechanism of TRPV4 activation. TRPV4 199 
cilia localisation was observed in isolated chondrocytes (Fig 3A). TRPV4 activation by 200 
mechanical loading, hypo-osmotic challenge or the TRPV4 agonist GSK101 (1 nM) 201 
increased TRPV4 cilia localisation while not significantly affecting protein expression, as 202 
shown by the increased mean intensity of ciliary TRPV4 (Fig. 3B, S10) and altered 203 
distribution profile of TRPV4 in proximal and distal regions of the axoneme (Fig. 3C) these 204 
data are suggestive of alterations in IFT.  205 
In isolated chondrocytes, IL-1β (1 ng/ml) treatment for 24 h induced a significant increase in 206 
primary cilia length (p<0.001) from a median value of 2.21 to 2.84 µm. This elongation was 207 
abolished by TRPV4 activation with GSK101 (Fig. 3D-E). IL-1β mediated cilia elongation 208 
was also blocked by mechanical loading (CTS, 0-10%, 0.33 Hz, Fig. 3G) and hypo-osmotic 209 
challenge (Fig 3H). Inhibition of TRPV4 with GSK205 restored IL-1β mediated cilia 210 
elongation in the presence of both mechanical loading (p<0.001, Fig. 3G), and hypo-osmotic 211 
challenge (p<0.001, Fig. 3H). GSK101, had no effect on cilia length in iso-osmotic conditions 212 
with or without IL-1β (Fig. 3E). GSK101 also had no effect on cilia prevalence for any of the 213 
treatment groups (Fig. S5A and D).  214 
TRPV4 activation inhibits inflammatory signalling in response to IL-1β through the 215 
regulation of HDAC6 and ciliary tubulin 216 
We next examined whether direct pharmaceutical activation of TRPV4 would replicate the 217 
anti-inflammatory effect of mechanical and osmotic loading.  IL-1β (1 ng/ml) induced the 218 
characteristic upregulation of NO and PGE2 release in isolated chondrocytes which was 219 
abolished by GSK101 (Fig. 4A and B). Similarly IL-1β induced COX2 expression was 220 
abolished by GSK101 (Fig. 4C). No effects on cell viability based on bright field microscopy 221 
(Fig. S6A) and DNA content were observed although cells appeared to have a more rounded 222 
morphology particularly at high concentrations (Fig. S6B).  223 
Previously, we identified a mechanistic role for HDAC6 activation and post-transcriptional 224 
tubulin modifications in  the anti-inflammatory effect of mechanical loading [5]. Similarly, 225 
GSK101 resulted in significant upregulation of HDAC6 activity (Fig. 4D) suggesting TRPV4-226 
mediated calcium signalling activates HDAC6. Consistent with this finding we observed 227 
significant tubulin deacetylation accompanied by a reduction in the pool of non-polymerized, 228 
soluble tubulin (Fig. 4E-F). Furthermore, the HDAC6 specific inhibitor, tubacin (500 nM), 229 
restored IL-1β mediated stimulation of NO release in GSK101-treated cells (Fig. 4G). These 230 
data suggest that GSK101 mimics the effects of mechanical loading on IL-1β inflammatory 231 
signalling, HDAC6 activation and tubulin modification. 232 
TRPV4 activation abolishes IL-1β mediated cartilage degradation and loss of 233 
mechanical properties 234 
We next determined whether pharmaceutical activation of TRPV4 could prevent cartilage 235 
degradation and loss of mechanical properties. Cartilage explants were treated with IL-1β for 236 
up to 12 d in the presence of 1 nM or 10 nM GSK101. Cartilage explant viability was 237 
maintained at these experimental doses (Fig. S7). In response to IL-1β treatment, significant 238 
NO release was observed (Fig. 5A, P<0.001) indicative of activation of inflammatory 239 
signalling. This response was accompanied by significant sGAG release indicative of 240 
cartilage degradation (Fig. 5B, P<0.001).  241 
We measured the viscoelastic properties of cartilage tissue using uniaxial unconfined 242 
compression to determine whether GSK101 could prevent the loss of mechanical properties 243 
induced by IL-1β. Cartilage explants exhibited a non-linear stress-strain graph represented 244 
by a tangent modulus of 15-20MPa (Fig 5C). This was followed by characteristic viscoelastic 245 
stress relaxation at 20% strain (Fig 5D) to a relaxation modulus of 2-3 MPa at 300 s 246 
representing 80% relaxation and a relaxation half-life of approximately 50 s (Fig. 5E-H). IL-247 
1β treatment resulted in dramatic loss of mechanical stiffness as shown by significant 248 
reductions in tangent modulus (p<0.001, Fig. 5E) and relaxation modulus (p<0.001, Fig. 5F), 249 
increased percentage relaxation (p<0.001, Fig. 5G) and a reduction in half-life (p<0.001, Fig. 250 
5H). 251 
GSK10 significantly inhibited the cumulative release of NO from cartilage explants in 252 
response to IL-1β treatment (p<0.001, Fig. 5A). Similarly the cumulative release of sGAG 253 
was significantly reduced (p<0.001) and loss of mechanical properties in response to IL-1β 254 
abolished, such that there was no significant difference in any of the biomechanical 255 
parameters with and without IL-1β. 256 
Discussion 257 
This study demonstrates that TRPV4 plays an important mechanistic role in the anti-258 
inflammatory effect of mechanical stimulation. TRPV4 inhibition restores IL-1β mediated pro-259 
inflammatory signalling in the presence of both mechanical and osmotic loading. Conversely, 260 
TRPV4 activation by GSK101 blocked the release of pro-inflammatory mediators in the 261 
absence of load in isolated cells and prevented cartilage degradation and loss of mechanical 262 
properties in an explant model. TRPV4 is activated by mechanical stimulation in the form of 263 
cyclic tensile strain or osmotic challenge and functions upstream of HDAC6 to modulate 264 
tubulin acetylation and polymerization which regulates IFT thereby suppressing IFT-265 
dependent IL-1β signalling. 266 
TRPV4 is expressed in bone marrow stem cells, osteoblasts, osteoclasts and chondrocytes, 267 
and is required for skeletal development  [10, 33].  TRPV4 belongs to the Transient Receptor 268 
Potential (TRP) superfamily which mediate cellular responses to a variety of environmental 269 
stimuli including heat [34], cell swelling [35], hypo-osmolality  [18, 36] and mechanical 270 
loading [7, 9] and results in elevated levels of intracellular Ca2+. Thus, TRPV4 is required for 271 
mechanotransduction. It promotes chondrocyte matrix production in response to dynamic 272 
compression [7], mediates the fluid shear induced osteogenic response in stem cells [9] and 273 
shear stress induced vasodilatation in endothelial cells [8]. 274 
In other tissues, TRPV4 activation is mostly reported to be pro-inflammatory. In airway 275 
epithelial cells, TRPV4 activates NF-κB signalling promoting progression of lung fibrosis [37]. 276 
Endogenous TRP channel agonists are detected in a lung injury model while TRPV4 277 
inhibition suppresses acid-induced pulmonary inflammation [38]. TRPV4 antagonists have 278 
been used to treat sepsis in mice by reducing production of TNF-α, IL-1 and IL-6 [16]. 279 
Moreover loss of TRPV4 function suppresses inflammatory fibrosis in mouse corneas [39].  280 
However, Xu et al. report that GSK101 prevents vascular inflammation and atherosclerosis, 281 
associated with inhibition of NO synthase and MAPK signalling [14]. TRPV4 is also well-282 
established to mediate inflammatory hyperalgesia (see review [40]) and is regarded as a 283 
promising target for novel analgesics.  284 
Consistent with our findings, pharmaceutical activation of TRPV4 has been shown to 285 
suppress NO release induced by lipopolysaccharide (LPS) in rat temporomandibular 286 
chondrocytes, whereas TRPV4 inhibition aggravates the inflammatory response to  LPS 287 
[13]. Clark et al. report that TRPV4 deficiency induces inflammation and disrupts cartilage 288 
matrix homeostasis. As such, TRPV4-/- mice exhibit a severe sex-dependent osteoarthritis 289 
(male mice are more susceptible) while the isolated chondrocytes fail to increase Ca2+ influx 290 
in response to hypo-osmotic challenge [11]. These mice exhibit  a more severe obesity-291 
induced osteoarthritis, compared to wild-type mice [12]. However other studies report 292 
osmotic challenge to be a pro-inflammatory signal.  Hubert et al observed induction of IL-8 in 293 
response to both hyper and hypo-osmotic stress [41] while hypo-osmotic stimulation of 294 
TRPV4 promoted PGE2 release in porcine chondrocytes [18] and the expression of IL-1β 295 
and IL-6 in bovine intervertebral disc cells [36], suggesting a pro-inflammatory role of 296 
TRPV4. We did observe a mild, transient increase in NO release in this study at 3 h hypo-297 
osmotic challenge however this had resolved and was not significantly different to the control 298 
at 24 h (Fig. S8). Interestingly we observed dose-dependent cytotoxicity of GSK101 with 299 
extended explant culture at concentrations above 10nM (Fig. S7). Low concentrations of 300 
GSK101 elicit multiple short peaks of Ca2+ signalling, which is more physiological compared 301 
with the large,  sustained peaks observed at higher concentrations which might explain this 302 
[42]. These observations suggest perhaps that only moderate, short-term modulation of 303 
TRPV4 will be chondroprotective. 304 
Servin-Vences et al suggest TRPV4 mechanosensitivity is dependent upon the type of 305 
stimulus applied [6]. Our data supports this hypothesis, complete abolition of NO release in 306 
response to IL-1β was observed following application of cyclic tensile strain (Figure 1), while 307 
hypo-osmotic challenge merely attenuated the response (Figure 2) suggesting TRPV4 308 
activation may be regulated distinct mechanisms and to different extents. Vriens et al report 309 
that TRPV4 activation in response to cell swelling is dependent upon arachidonic acid 310 
release [43] whereas Servin-Vences et al suggest direct channel gating occurs in response 311 
to membrane deflection [6]. 312 
The mechanosensitive ion channel PIEZO1 reportedly induces TRPV4 channel opening [44]. 313 
PIEZO1 is activated chondrocytes following injurious loading and is suggested to play a 314 
greater role in chondroprotection than TRPV4 [6, 45]. It is possible the more pronounced 315 
anti-inflammatory effects of cyclic tensile strain observed in this study are the result of further 316 
TRPV4 activation downstream of this channel, which could be explored in future studies. 317 
However, while activation of PIEZO1 reportedly influences ciliogenesis [46] studies in 318 
osteocytes indicate that it does not interact with TRPV4 in the cilium [47]. 319 
TRPV4 cilia localisation was observed with greater localisation evident at to the ciliary base 320 
(Fig. 3C). TRPV4 activation altered this distribution such that localisation to the base or tip of 321 
the axoneme was not significantly different indicative of altered protein trafficking/IFT (Fig. 322 
3C). TRPV4 activation is coupled with translocation of TRPV4 to plasma membrane [48], in 323 
this study we observed increased TRPV4 labelling in the ciliary membrane (Fig. 3AB). 324 
Chemical deletion of primary cilia with chloral hydrate fully abolishes Ca2+ signalling in 325 
response to TRPV4 activation [18] thus increased ciliary TRPV4 may be important for 326 
signalling.  327 
HDAC6 is enriched within primary cilia catalysing tubulin de-acetylation and polymerization 328 
to regulate cilia resorption [27-29]. In this study, mechanical, hypo-osmotic and 329 
pharmaceutical activation of TRPV4 blocked cilia elongation in response to IL-1β. IFT and 330 
cilia elongation is required for IL-1β mediated inflammatory signalling and downstream NF-331 
κB signalling [5, 23, 24], therefore we suggest the anti-inflammatory effects of TRPV4 332 
activation regulate IFT and associated signalling via HDAC6 dependent modulation of ciliary 333 
tubulin. Previous studies demonstrate that GSK101 activates Ca2+ signalling in isolated 334 
chondrocytes [6, 17, 49], while GSK205 inhibits this response and blocks Ca2+ signalling in 335 
response to mechanical or osmotic loading [18, 50, 51]. While Ca2+ signalling was not 336 
assessed in the current study, we hypothesise that Ca2+ levels may regulate HDAC activity 337 
through activation of upstream kinases such as Ca2+/Calmodulin dependent kinase (CaMK), 338 
protein kinase D (PKD) and Aurora A kinase-dependent (AURKA) [27-29, 52-55]. Studies 339 
suggest TRPV4 stimulation with GSK101 promotes ERK/MAPK signalling in lung epithelial 340 
cells and cancer cells [56] and PKC activity in endothelial cells [57] which phosphorylate 341 
HDAC6 resulting in increased deacetylation activity [58, 59]. Indeed, increased HDAC6 342 
activity was observed in response to GSK101 (Fig. 4D). 343 
In conclusion, this study demonstrates a role for TRPV4 activation in the anti-inflammatory 344 
mechanism of loading. In addition to providing new mechanistic understanding of this 345 
pathway, this study identifies TRPV4 as a potential therapeutic target and demonstrates that 346 
pharmaceutical activation of this protein could regulate inflammation and other IFT-347 
dependent pathways involved in cartilage disease. 348 
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Figure 1. Cyclic tensile strain inhibits IL-1β mediated NO and PGE2 release via a TRPV4 dependent 
pathway in isolated chondrocytes.  
The TRPV4 antagonist, GSK205 (10 μM), abolishes the anti-inflammatory effects of mechanical loading 
(CTS, 10%, 0.33 Hz) at 1 ng/ml IL-1β on (A) nitrite and (B) PGE2 release at 24 h. Data represents mean 
± SD for n=6 wells per group using cells isolated from 2 different donors. Statistics: Three-way ANOVA 
and post hoc Tukey’s test. # represents statistically significant difference between IL-1β treated and 
corresponding untreated cells. 
Figure 2. Hypo-osmotic challenge inhibits IL-1β mediated NO release via a TRPV4 dependent 
pathway in isolated chondrocytes and cartilage explants  
The TRPV4 antagonist, GSK205, suppresses the anti-inflammatory effects of hypo- osmotic challenge. 
Nitrite levels measured in the media for (A) isolated cells and (C) cartilage explants in hypo- or iso-
osmotic media. Chondrocytes and cartilage explants were treated with and without IL-1β (1 ng/ml) 
for 24 h and 12 d respectively with and without the TRPV4 inhibitor GSK205 (10 μM). Hypo-osmotic 
challenge had no effect on cell viability as determined by (B) bright filed images of isolated 
chondrocytes (D) confocal microscopy of explants stained with Calcein-AM (live cells, green) and 
ethidium homodimer (dead cells, red). Scale bar represents 100 µm. Data represents mean ± SD for 
n=6 separate wells (A) or n=8 separate explants (C) using cells/explants isolated from 2 different 
donors. Statistics: Three-way ANOVA and post hoc Tukey’s test. # represents statistically significant 
difference between IL-1β treated and corresponding untreated cells. 
Figure 3. TRPV4 activation increases cilia expression of TRPV4 and inhibits cilia elongation in 
response to IL-1β 
Primary articular chondrocytes were subjected to mechanical loading (CTS, 10%, 0.33 Hz), hypo-
osmotic challenge (200 mOsm) or the TRPV4 agonist 1 nM GSK101 for 24 h. (A) Representative 
maximum intensity projection of confocal images showing co-localisation of Acet-α-tubulin (Red) and 
TRPV4 (Green).  Scale bar represents 1 μm. Pharmaceutical activation of TRPV4 increased the (B) 
mean intensity of TRPV4 labelling on primary cilia (n=20-30 cilia) and (C) altered the distribution of 
TRPV4 on the cilium (n=20-30 cilia). (D) Representative maximum intensity projection confocal 
microscopy images of isolated chondrocytes treated with ± 1 ng/ml IL-1β ±1 nM GSK101 then labelled 
for acetylated α-tubulin (red) and counter stained with DAPI (blue). Scale bar represents 10 μm. (E) 
Primary cilia length and (F) associated % elongation were measured at 24 h. % cilia elongation results 
showing IL-1β induced change in cilia length for cells cultured (G) with and without mechanical 
loading and in (H) iso- and hypo-osmotic media. For % cilia elongation, data represents cilia length 
change in the presence of IL-1β (1 ng/ml, 24 h) normalised to median values in corresponding 
condition without IL-1β. Box plots are displayed as median, with error bars depicting min/max values 
(for E-H, n=70-130 cilia). Statistics: One-way ANOVA (B) and Two-way ANOVA (D, E, G and H) with post 
hoc Tukey’s test and T-test (C, F).  
  
figure legends
Figure 4. TRPV4 activation abolishes IL-1β inflammatory signalling via HDAC6 activation 
Levels of (A) nitrite (B) PGE2 and (C) COX-2 expression associated with isolated chondrocytes ±IL-1β (1 
ng/ml) in the presence or absence of GSK101 for 24 hrs. GSK101 promotes (D) HDAC6 activity, 
induces the (E) de-acetylation and (E) de-polymerization of α-tubulin, as measured by western blot of 
acetylated α-tubulin (Acet α-Tub), α-tubulin (α-Tub) and non-polymerized α-tubulin. Full western 
blots can be found in supplementary figure S9. (G) HDAC6 inhibition with tubacin (500 nM) abolished 
the anti-inflammatory effect of GSK101 on NO release. Data represents mean ± SD for n=6 (A, B, D 
and G) and n=4 (C, E and F) Statistics: Two-way ANOVA and post hoc Tukey’s test (A-C), T-test (D-G. # 
represents statistically significant difference between IL-1β treated and corresponding untreated 
cells. 
Figure 5. TRPV4 activation suppresses IL-1β induced NO release, matrix degradation and loss of 
mechanical properties in cartilage explants. 
Full-depth cartilage explants were treated with the TRPV4 agonist GSK101 (0, 1, 10 nM) in the 
presence or absence of 1 ng/ml IL-1β for 12 d. The nitrite (A) and sGAG (B) content of the culture 
media was measured and normalised to wet weight. Cartilage explants were compressed to obtain 
the stress-strain (C) and stress-relaxation (D) plots, for the calculation of cartilage mechanical 
properties. The responding mechanical properties of tangent modulus from 18-20% compression (E), 
relaxation modulus (F), percentage relaxation (G) and half-life (H). Data represents mean ± SD, n=6-12 
explants from 4 different donors. Statistics: Two-way ANOVA with post hoc Tukey’s test. # represents 
statistically significant difference between IL-1β treated and corresponding untreated cells. 
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Introduction  1 
Osteoarthritis (OA) effects over 4.4 million people in the UK alone representing significant 2 
economic cost [1]. Cartilage health is maintained in response to mechanical stimuli, articular 3 
cartilage is routinely exposed to a wide array of dynamic mechanical loading consisting of 4 
compressive, shear and tensile strains as well as associated alterations in fluid shear and 5 
osmolality [2]. Mechanical loading in the form of compression or tensile strain is anti-6 
inflammatory in chondrocytes  and blocks the release of the pro-inflammatory mediator’s 7 
nitric oxide (NO) and prostaglandin E2 (PGE2) in response to interleukin-1β (IL-1β) [3-5]. 8 
Inflammatory signalling contributes to cartilage degradation in OA thus understanding the 9 
link between mechanical loading and inflammation will have significant therapeutic impact. 10 
The osmotic-sensitive Ca2+ ion channel Transient Receptor Potential Vanilloid 4 (TRPV4) is 11 
highly expressed in articular chondrocytes and is activated by mechanical stimuli  [6, 7]. 12 
TRPV4 is required for mechanotransduction in chondrocytes and other cells types [7-9]. It 13 
mediates the regulation of pro-anabolic and anti-catabolic genes promoting matrix 14 
production and accumulation in agarose-embedded chondrocytes [7, 9]. TRPV4 mutations 15 
result in human skeletal dysplasia suggesting a role in bone development (for review see 16 
[10]). Indeed, chondrocytes from TRPV4-/- mice exhibit loss of osmosensitivity accompanied 17 
by joint degeneration indicating a central role for this channel protein in maintaining joint 18 
homeostasis [11, 12]. Pharmaceutical activation of TRPV4 inhibits NO release in response 19 
to inflammatory cytokines suggesting a potential mechanistic role in the anti-inflammatory 20 
effects of mechanical loading  [13, 14]. However, in apparent contradiction of these findings 21 
TRPV4 inhibition exerts an anti-inflammatory effect in the cardiovascular system, lung and 22 
peripheral nervous system [15-17]. This study therefore aims to clarify the regulatory role of 23 
TRPV4 in cartilage inflammatory signalling.   24 
TRPV4 localises to the plasma membrane and primary cilium, a small microtubule based 25 
signalling compartment present at the cell surface [18, 19]. Primary cilia have been 26 
Manuscript with marked changes
implicated in both chondrocyte mechanotransduction [20-22] and inflammatory signalling 27 
[23-26]. The cytoplasmic tubulin deacetylase histone deacetylase 6 (HDAC6) is enriched 28 
within the cilium and modulates cilia resorption through de-acetylation and polymerization of 29 
ciliary tubulin [27-29]. Post translational modification of ciliary tubulin influences intraflagellar 30 
transport (IFT), the microtubule based motility present within the cilium required for cilia-31 
mediated signalling [30, 31]. Previously we report that mechanical loading counteracts 32 
inflammatory signalling in response to the pro-inflammatory cytokine interleukin 1β (IL-1β) 33 
via HDAC6 activation in association with alterations in IFT/cilia [5]. A role for TRPV4 in this 34 
pathway has not previously been identified. 35 
In the present study, we demonstrate for the first time that TRPV4 activation by cyclic tensile 36 
strain, hypo-osmotic challenge or the TRPV4 agonist GSK1016790A inhibits pro-37 
inflammatory IL-1β signalling and cartilage degradation associated with alterations in primary 38 
cilia elongation. TRPV4 may therefore provide a novel target for the treatment of joint 39 
disease and other inflammatory pathologies. 40 
Methods 41 
Antibodies and reagents 42 
Chondrocytes were treated with interleukin-1β (IL-1β, 200-01B; Peprotech, London, UK), 43 
TRPV4 antagonist GSK205 (616522; Merck Millipore, London, UK) and agonist 44 
GSK1016790A (GSK101, G0798; Sigma Aldrich, Poole, UK). Antibodies for 45 
immunocytochemistry: acetylated α-tubulin (1:2000, T7451, Sigma Aldrich, Poole, UK) and 46 
TRPV4 (1:200, SAB2104243, Sigma Aldrich). Nuclei were counterstained with 4′,6-47 
diamidino-2-phenylindole  (DAPI, Sigma Aldrich). Antibodies for western blotting: acetylated 48 
α-tubulin (1:1000, T7451, Sigma Aldrich) and α-tubulin (1:1000, ab4074, Abcam, Cambridge, 49 
UK). 50 
Cartilage explant and chondrocyte culture  51 
Bovine cartilage explants and chondrocytes were obtained from 16 month steers as 52 
previously described [28]. Full depth articular cartilage was removed from the proximal 53 
surface of the metacarpal phalangeal joint and chondrocytes isolated by enzymatic 54 
digestion. Explants were harvested using a 5 mm diameter biopsy punch (BP-50F, Selles 55 
Medical Ltd, UK).  Both were cultured at 37 °C, 5% CO2 in Dulbeccos Minimal Essential 56 
Medial (DMEM, D5921, Sigma-Aldrich, Poole, UK) supplemented with 10% (v/v) foetal calf 57 
serum (FCS, F7524, Gibco, Paisley, UK), 1.9 mM L-glutamine (G7513), 96 U/ml penicillin 58 
(P4333, All Sigma-Aldrich, Poole, UK). Explants were rested for 2 d prior to experimentation 59 
while isolated chondrocytes were cultured to confluence. 60 
Application of cyclic tensile strain 61 
Isolated chondrocytes were cultured on collagen coated flexible elastomeric membranes and 62 
subjected to uniform, equibiaxial cyclic tensile strain (CTS) applied using the Flexcell 5000T 63 
system (Dunn Labortechnik GMbH).Cells were subjected to 0-10% strain for 24 h at 0.33 Hz.  64 
Application of osmotic loading 65 
Isolated cells were cultured for 24 h without serum in osmotically adjusted media at 200, 315 66 
or 400 mOsm, hereafter referred as hypo-, iso- or hyper- osmotic media respectively. 67 
Explants were cultured for up to 12 d under similar conditions with the addition of serum to 68 
maintain chondrocyte viability resulting in a slightly higher osmolarity of 318 mOsm for the 69 
iso-osmotic media. The osmolarity of all solutions was adjusted by adding D-mannitol 70 
(M4125, Sigma-Aldrich) or distilled water and measured using a freezing point depression 71 
osmometer.  72 
Biochemical analysis of NO, PGE2 and sGAG release 73 
Nitric Oxide (NO) release was assessed using the Griess assay based on quantification of 74 
nitrite (NO2), the stable product of NO degradation. Nitrite content was quantified against a 75 
sodium nitrite standard curve using the Galaxy Fluorstar spectrophotometer (BMG Labtech, 76 
UK). An immunoassay kit (KGE004B, R&D Systems, UK) was used to quantify PGE2 77 
concentrations in the media according to the manufacturer’s instructions. Results were 78 
corrected for non-specific binding and calibrated using a PGE2 standard curve. The release 79 
of sGAG into the culture media was quantified using the dimethylmethyleneblue (DMMB) 80 
assay against a chondroitin sulphate standard curve (6-sulphate:4-sulphate; 0.33:1; Sigma–81 
Aldrich).  82 
Immunocytochemistry, live imaging and confocal microscopy 83 
For immunocytochemistry, samples were fixed with 4% paraformaldehyde for 10 min, 84 
permeabilised for 5 min with 0.5% triton-X100/phosphate buffered saline (PBS) then blocked 85 
with 5% goat serum/PBS for 1 h. Primary antibody was incubated at 4°C overnight followed 86 
by appropriate Alexa Fluor conjugated secondary antibodies (Molecular Probes) for 1 h at 87 
room temperature. Cells were counterstained with 1 µg/ml DAPI for 5 min. For live imaging, 88 
cell viability was assessed by live/dead staining. Explants were incubated for 30 min with 5 89 
µM Calcein AM and 5 µM Ethidium homodimer-1 (EthD-1) prepared in appropriate osmotic 90 
adjusted media, washed and immediately imaged. Samples were imaged using a Zeiss 710 91 
ELYRA PS.1 microscope. For cilia analysis, samples were imaged using an x63/1.4 NA 92 
objective to generate confocal z-sections made throughout the cell depth (approximately 20 93 
sections) using 0.25 μm step size with an image format of 1024 x 1024 yielding a pixel size 94 
of 0.13 x 0.13 μm (image size approximately 135 x 135 μm). Cilia length and prevalence was 95 
quantified from resulting maximum projection images using Image J software (National 96 
Institutes of Health, Maryland, USA).  97 
Western blotting 98 
Cells were lysed in RIPA buffer (R0278, Sigma Aldrich) and total protein quantified by 99 
Bicinchoninic acid (BCA) assay. For the fractionation of soluble and polymerized tubulin, 100 
extraction buffer A (137 mM NaCl, 20 mM Tris-HCl, 1% Triton X-100, and 10% glycerol) was 101 
added to cells at 4 °C for 3 min, plates were gently swirled and the buffer removed and 102 
saved as the soluble tubulin  fraction. Immediately after, extraction buffer B (buffer A + 1% 103 
SDS) was added for 1 min, the remaining sample was scraped, incubated on ice for 30 min 104 
and saved as the polymerized  tubulin fraction. 105 
SDS–PAGE was performed under reducing conditions and proteins transferred to 106 
nitrocellulose membranes. Membranes were blocked in odyssey blocking buffer (Li-Cor 107 
Cambridge, UK) prior to overnight incubation with primary antibodies and infrared secondary 108 
antibodies (Li-Cor). Proteins were visualized using the Li-Cor Odyssey and quantified using 109 
Image Studio Lite software (Li-Cor). 110 
HDAC6 activity measurement 111 
A commercial fluorometric assay kit (K466-100, Biovision) was used to measure HDAC6 112 
activity according to the manufacturer’s instructions. This assay determines enzyme activity 113 
by exploiting the selectivity of tubacin for HDAC6 in combination with a fluorescent synthetic 114 
acetylated-peptide substrate. Cultures were lysed, a 10 µl aliquot was mixed with either 115 
acetylated substrate (sample) or with 2 μM tubacin and acetylated substrate (inhibitor 116 
control) then incubated for 30 min at 37°C. The deacetylase-dependent release of a 7-117 
amino-4-trifluoromethylcoumarin fluorophore (excitation/emission at 350/490 nm) was then 118 
measured on a Galaxy Fluorstar spectrophotometer (BMG Labtech, UK) and HDAC6 activity 119 
calculated as [sample-inhibitor control]. 120 
Mechanical testing of cartilage explants 121 
The mechanical behaviour of individual cartilage explants was measured using an MTS, 122 
Bionix 100. A 2 mm diameter core was cut from the centre of each 5 mm diameter cartilage 123 
explant and a tare load of 0.01 N applied to each explant which was then hydrated in culture 124 
media. The explants were subjected to a 20% uniaxial unconfined compressive strain (20% 125 
/min). This was followed by a stress relaxation period at constant 20% strain in which the 126 
load was recorded for a further 300 s. The load was recorded throughout the test at a 127 
sampling frequency of 60 Hz.  Stress–strain and stress–time curves were generated for each 128 
specimen and the following mechanical properties of the cartilage determined: 129 












The relaxation half-life was calculated as the time from the start of the relaxation phase until 133 
stress reduced to half the peak value. 134 
Statistical analyses 135 
The sample size for each experiment was chosen based on previous studies [5, 32] where 136 
analysis of cartilage degradation by biochemistry, immunohistochemistry and mechanical 137 
testing demonstrated that  6-8 samples/group is sufficient to detect a 25% difference in 138 
cartilage matrix catabolism at 80% power and a significance of p<0.05. Data analysis was 139 
conducted using GraphPad Prism version 8 (GraphPad software, La Jolla California USA, 140 
www.graphpad.com). Normality testing (Kolmogorov Smirnov test) was performed to confirm 141 
that data exhibited Gaussian distribution. For data sets that were not normally distributed, 142 
namely cilia length data, Box Cox transformation (λ=0.5) was performed prior to statistical 143 
analyses. Statistical significance was determined by T-Test, One-way, Two-way or Three-144 
way ANOVA as appropriate with post-hoc Tukey’s multiple comparisons performed to 145 
identify significant differences between groups. Statistically significant differences were 146 
determined based on a threshold of *= p<0.05, **=p<0.01 and ***=p=0.001. Data is 147 
presented as mean ± standard deviation (SD) unless otherwise stated.  148 
Results 149 
TRPV4 activation is required for the anti-inflammatory effects of mechanical loading 150 
in isolated chondrocytes 151 
IL-1β treatment (24 h) resulted in significant, dose-dependent release of NO and PGE2 (Fig. 152 
1AB, S1AB). In response to 1 ng/ml IL-1β isolated chondrocytes exhibited a 3.04-fold 153 
increase in nitrite levels indicative of NO release (Fig. 1A), and a 4.84-fold increase in PGE2 154 
release (Fig. 1B) which increased to 11.48- and 7.37-fold respectively in response to 10 155 
ng/ml IL-1β (Fig. S1A-B). Consistent with previous studies [5] this response was significantly 156 
reduced by mechanical loading in the form of CTS. IL-1β induced NO release was abolished 157 
by CTS such that there was no statistically significant effect at either 1 or 10 ng/ml (Fig. 1A, 158 
S1A). PGE2 release was completely inhibited by CTS at 1 ng/ml IL-1β (Fig. 1B) but only 159 
partially suppressed at 10 ng/ml (Fig. S1B).  160 
Simultaneous treatment with the TRPV4 antagonist GSK205 (10 µM) abolished the anti-161 
inflammatory effects of mechanical loading (Figure 1, S1). While GSK205 had no effect on 162 
NO or PGE2 release in unloaded cells with or without IL-1β, in loaded cells the IL-1β 163 
response was restored such that NO (Fig. 1A and S1A) and PGE2 release (Fig. 1B, S1B) 164 
were significantly increased by IL-1β. Neither IL-1β nor GSK205 treatment in the presence 165 
or absence of CTS influenced TRPV4 protein levels (Fig. S10). These data indicate the anti-166 
inflammatory effects of mechanical loading are mediated by TRPV4 activation. 167 
TRPV4 activation is required for the anti-inflammatory effects of hypo-osmotic loading 168 
in isolated chondrocytes and cartilage explants 169 
Isolated chondrocytes were treated with hyper-osmotic media (400 mOsm), hypo-osmotic 170 
(200 mOsm) or iso-osmotic media (315 mOsm) for 24 h (Figure 2AB, S2). Hyper-osmotic 171 
challenge had no significant effect on NO release, with or without IL-1β relative to the iso-172 
osmotic control (Fig. S2, S3). By contrast, hypo-osmotic challenge significantly attenuated 173 
the pro-inflammatory response to IL-1β (1 ng/ml), such that the increase in NO release at 24 174 
h was significantly reduced (p<0.001, Fig. 2A S2A). Hypo-osmotic challenge had no 175 
apparent effect on cell viability compared to control conditions based on brightfield 176 
microscopy (Figure 2B). In the presence of GSK205, the anti-inflammatory effect of hypo-177 
osmotic challenge on IL-1β induced NO release was completely inhibited by GSK205 such 178 
that the induction of NO release was not significantly different to control conditions (Fig. 2A). 179 
In the absence of IL-1β, GSK205 also had no effect on baseline NO or PGE2 levels (Fig. 180 
S2). 181 
In cartilage explants, hypo-osmotic challenge significantly reduced IL-1β induced NO release 182 
(Fig. 2C, p<0.001) such that there was no significant difference between IL-1β treated and 183 
untreated explants (Fig. 2C, S4A). In line with these findings hypo-osmotic challenge 184 
blocked the IL-1β mediated release of sGAG into the media, indicative of a reduction in 185 
extracellular matrix degradation (Fig. S4B). Chondrocyte viability was maintained throughout 186 
the experiment as determined by live/dead staining (Fig. 2D). Consistent with isolated cells, 187 
hyper-osmotic challenge (400 mOsm, 12 d) had no effect on NO or sGAG release in the 188 
presence or absence of 1 ng/ml IL-1β (Fig. S4). GSK205 treatment restored IL-1β-induced 189 
NO release in hypo-osmotic media (Fig. 2C) thus blocking the anti-inflammatory effect of 190 
osmotic challenge. Interestingly, GSK205 further increased IL-1β-induced NO release in iso-191 
osmotic, control media a response not seen in isolated cells (Fig. 2C). Together these data 192 
indicate the anti-inflammatory effects of hypo-osmotic loading are also mediated by TRPV4 193 
activation. 194 
TRPV4 activation is associated with altered primary cilia localisation and regulates 195 
cilia length  196 
IL-1β induces primary cilia elongation in articular chondrocytes and mediates downstream 197 
catabolic NF-κB signalling through regulation of IFT [5, 23, 24]. We therefore examined the 198 
involvement of primary cilia in the anti-inflammatory mechanism of TRPV4 activation. TRPV4 199 
cilia localisation was observed in isolated chondrocytes (Fig 3A). TRPV4 activation by 200 
mechanical loading, hypo-osmotic challenge or the TRPV4 agonist GSK101 (1 nM) 201 
increased TRPV4 cilia localisation while not significantly affecting protein expression, as 202 
shown by the increased mean intensity of ciliary TRPV4 (Fig. 3B, S10) and altered 203 
distribution profile of TRPV4 in proximal and distal regions of the axoneme (Fig. 3C) these 204 
data are suggestive of alterations in IFT.  205 
In isolated chondrocytes, IL-1β (1 ng/ml) treatment for 24 h induced a significant increase in 206 
primary cilia length (p<0.001) from a median value of 2.21 to 2.84 µm. This elongation was 207 
abolished by TRPV4 activation with GSK101 (Fig. 3D-E). IL-1β mediated cilia elongation 208 
was also blocked by mechanical loading (CTS, 0-10%, 0.33 Hz, Fig. 3G) and hypo-osmotic 209 
challenge (Fig 3H). Inhibition of TRPV4 with GSK205 restored IL-1β mediated cilia 210 
elongation in the presence of both mechanical loading (p<0.001, Fig. 3G), and hypo-osmotic 211 
challenge (p<0.001, Fig. 3H). GSK101, had no effect on cilia length in iso-osmotic conditions 212 
with or without IL-1β (Fig. 3E). GSK101 also had no effect on cilia prevalence for any of the 213 
treatment groups (Fig. S5A and D).  214 
TRPV4 activation inhibits inflammatory signalling in response to IL-1β through the 215 
regulation of HDAC6 and ciliary tubulin 216 
We next examined whether direct pharmaceutical activation of TRPV4 would replicate the 217 
anti-inflammatory effect of mechanical and osmotic loading.  IL-1β (1 ng/ml) induced the 218 
characteristic upregulation of NO and PGE2 release in isolated chondrocytes which was 219 
abolished by GSK101 (Fig. 4A and B). Similarly IL-1β induced COX2 expression was 220 
abolished by GSK101 (Fig. 4C). No effects on cell viability based on bright field microscopy 221 
(Fig. S6A) and DNA content were observed although cells appeared to have a more rounded 222 
morphology particularly at high concentrations (Fig. S6B).  223 
Previously, we identified a mechanistic role for HDAC6 activation and post-transcriptional 224 
tubulin modifications in  the anti-inflammatory effect of mechanical loading [5]. Similarly, 225 
GSK101 resulted in significant upregulation of HDAC6 activity (Fig. 4D) suggesting TRPV4-226 
mediated calcium signalling activates HDAC6. Consistent with this finding we observed 227 
significant tubulin deacetylation accompanied by a reduction in the pool of non-polymerized, 228 
soluble tubulin (Fig. 4E-F). Furthermore, the HDAC6 specific inhibitor, tubacin (500 nM), 229 
restored IL-1β mediated stimulation of NO release in GSK101-treated cells (Fig. 4G). These 230 
data suggest that GSK101 mimics the effects of mechanical loading on IL-1β inflammatory 231 
signalling, HDAC6 activation and tubulin modification. 232 
TRPV4 activation abolishes IL-1β mediated cartilage degradation and loss of 233 
mechanical properties 234 
We next determined whether pharmaceutical activation of TRPV4 could prevent cartilage 235 
degradation and loss of mechanical properties. Cartilage explants were treated with IL-1β for 236 
up to 12 d in the presence of 1 nM or 10 nM GSK101. Cartilage explant viability was 237 
maintained at these experimental doses (Fig. S7). In response to IL-1β treatment, significant 238 
NO release was observed (Fig. 5A, P<0.001) indicative of activation of inflammatory 239 
signalling. This response was accompanied by significant sGAG release indicative of 240 
cartilage degradation (Fig. 5B, P<0.001).  241 
We measured the viscoelastic properties of cartilage tissue using uniaxial unconfined 242 
compression to determine whether GSK101 could prevent the loss of mechanical properties 243 
induced by IL-1β. Cartilage explants exhibited a non-linear stress-strain graph represented 244 
by a tangent modulus of 15-20MPa (Fig 5C). This was followed by characteristic viscoelastic 245 
stress relaxation at 20% strain (Fig 5D) to a relaxation modulus of 2-3 MPa at 300 s 246 
representing 80% relaxation and a relaxation half-life of approximately 50 s (Fig. 5E-H). IL-247 
1β treatment resulted in dramatic loss of mechanical stiffness as shown by significant 248 
reductions in tangent modulus (p<0.001, Fig. 5E) and relaxation modulus (p<0.001, Fig. 5F), 249 
increased percentage relaxation (p<0.001, Fig. 5G) and a reduction in half-life (p<0.001, Fig. 250 
5H). 251 
GSK10 significantly inhibited the cumulative release of NO from cartilage explants in 252 
response to IL-1β treatment (p<0.001, Fig. 5A). Similarly the cumulative release of sGAG 253 
was significantly reduced (p<0.001) and loss of mechanical properties in response to IL-1β 254 
abolished, such that there was no significant difference in any of the biomechanical 255 
parameters with and without IL-1β. 256 
Discussion 257 
This study demonstrates that TRPV4 plays an important mechanistic role in the anti-258 
inflammatory effect of mechanical stimulation. TRPV4 inhibition restores IL-1β mediated pro-259 
inflammatory signalling in the presence of both mechanical and osmotic loading. Conversely, 260 
TRPV4 activation by GSK101 blocked the release of pro-inflammatory mediators in the 261 
absence of load in isolated cells and prevented cartilage degradation and loss of mechanical 262 
properties in an explant model. TRPV4 is activated by mechanical stimulation in the form of 263 
cyclic tensile strain or osmotic challenge and functions upstream of HDAC6 to modulate 264 
tubulin acetylation and polymerization which regulates IFT thereby suppressing IFT-265 
dependent IL-1β signalling. 266 
TRPV4 is expressed in bone marrow stem cells, osteoblasts, osteoclasts and chondrocytes, 267 
and is required for skeletal development  [10, 33].  TRPV4 belongs to the Transient Receptor 268 
Potential (TRP) superfamily which mediate cellular responses to a variety of environmental 269 
stimuli including heat [34], cell swelling [35], hypo-osmolality  [18, 36] and mechanical 270 
loading [7, 9] and results in elevated levels of intracellular Ca2+. Thus, TRPV4 is required for 271 
mechanotransduction. It promotes chondrocyte matrix production in response to dynamic 272 
compression [7], mediates the fluid shear induced osteogenic response in stem cells [9] and 273 
shear stress induced vasodilatation in endothelial cells [8]. 274 
In other tissues, TRPV4 activation is mostly reported to be pro-inflammatory. In airway 275 
epithelial cells, TRPV4 activates NF-κB signalling promoting progression of lung fibrosis [37]. 276 
Endogenous TRP channel agonists are detected in a lung injury model while TRPV4 277 
inhibition suppresses acid-induced pulmonary inflammation [38]. TRPV4 antagonists have 278 
been used to treat sepsis in mice by reducing production of TNF-α, IL-1 and IL-6 [16]. 279 
Moreover loss of TRPV4 function suppresses inflammatory fibrosis in mouse corneas [39].  280 
However, Xu et al. report that GSK101 prevents vascular inflammation and atherosclerosis, 281 
associated with inhibition of NO synthase and MAPK signalling [14]. TRPV4 is also well-282 
established to mediate inflammatory hyperalgesia (see review [40]) and is regarded as a 283 
promising target for novel analgesics.  284 
Consistent with our findings, pharmaceutical activation of TRPV4 has been shown to 285 
suppress NO release induced by lipopolysaccharide (LPS) in rat temporomandibular 286 
chondrocytes, whereas TRPV4 inhibition aggravates the inflammatory response to  LPS 287 
[13]. Clark et al. report that TRPV4 deficiency induces inflammation and disrupts cartilage 288 
matrix homeostasis. As such, TRPV4-/- mice exhibit a severe sex-dependent osteoarthritis 289 
(male mice are more susceptible) while the isolated chondrocytes fail to increase Ca2+ influx 290 
in response to hypo-osmotic challenge [11]. These mice exhibit  a more severe obesity-291 
induced osteoarthritis, compared to wild-type mice [12]. However other studies report 292 
osmotic challenge to be a pro-inflammatory signal.  Hubert et al observed induction of IL-8 in 293 
response to both hyper and hypo-osmotic stress [41] while hypo-osmotic stimulation of 294 
TRPV4 promoted PGE2 release in porcine chondrocytes [18] and the expression of IL-1β 295 
and IL-6 in bovine intervertebral disc cells [36], suggesting a pro-inflammatory role of 296 
TRPV4. We did observe a mild, transient increase in NO release in this study at 3 h hypo-297 
osmotic challenge however this had resolved and was not significantly different to the control 298 
at 24 h (Fig. S8). Interestingly we observed dose-dependent cytotoxicity of GSK101 with 299 
extended explant culture at concentrations above 10nM (Fig. S7). Low concentrations of 300 
GSK101 elicit multiple short peaks of Ca2+ signalling, which is more physiological compared 301 
with the large,  sustained peaks observed at higher concentrations which might explain this 302 
[42]. These observations suggest perhaps that only moderate, short-term modulation of 303 
TRPV4 will be chondroprotective. 304 
Servin-Vences et al suggest TRPV4 mechanosensitivity is dependent upon the type of 305 
stimulus applied [6]. Our data supports this hypothesis, complete abolition of NO release in 306 
response to IL-1β was observed following application of cyclic tensile strain (Figure 1), while 307 
hypo-osmotic challenge merely attenuated the response (Figure 2) suggesting TRPV4 308 
activation may be regulated distinct mechanisms and to different extents. Vriens et al report 309 
that TRPV4 activation in response to cell swelling is dependent upon arachidonic acid 310 
release [43] whereas Servin-Vences et al suggest direct channel gating occurs in response 311 
to membrane deflection [6]. 312 
The mechanosensitive ion channel PIEZO1 reportedly induces TRPV4 channel opening [44]. 313 
PIEZO1 is activated chondrocytes following injurious loading and is suggested to play a 314 
greater role in chondroprotection than TRPV4 [6, 45]. It is possible the more pronounced 315 
anti-inflammatory effects of cyclic tensile strain observed in this study are the result of further 316 
TRPV4 activation downstream of this channel, which could be explored in future studies. 317 
However, while activation of PIEZO1 reportedly influences ciliogenesis [46] studies in 318 
osteocytes indicate that it does not interact with TRPV4 in the cilium [47]. 319 
TRPV4 cilia localisation was observed with greater localisation evident at to the ciliary base 320 
(Fig. 3C). TRPV4 activation altered this distribution such that localisation to the base or tip of 321 
the axoneme was not significantly different indicative of altered protein trafficking/IFT (Fig. 322 
3C). TRPV4 activation is coupled with translocation of TRPV4 to plasma membrane [48], in 323 
this study we observed increased TRPV4 labelling in the ciliary membrane (Fig. 3AB). 324 
Chemical deletion of primary cilia with chloral hydrate fully abolishes Ca2+ signalling in 325 
response to TRPV4 activation [18] thus increased ciliary TRPV4 may be important for 326 
signalling.  327 
HDAC6 is enriched within primary cilia catalysing tubulin de-acetylation and polymerization 328 
to regulate cilia resorption [27-29]. In this study, mechanical, hypo-osmotic and 329 
pharmaceutical activation of TRPV4 blocked cilia elongation in response to IL-1β. IFT and 330 
cilia elongation is required for IL-1β mediated inflammatory signalling and downstream NF-331 
κB signalling [5, 23, 24], therefore we suggest the anti-inflammatory effects of TRPV4 332 
activation regulate IFT and associated signalling via HDAC6 dependent modulation of ciliary 333 
tubulin. Previous studies demonstrate that GSK101 activates Ca2+ signalling in isolated 334 
chondrocytes [6, 17, 49], while GSK205 inhibits this response and blocks Ca2+ signalling in 335 
response to mechanical or osmotic loading [18, 50, 51]. While Ca2+ signalling was not 336 
assessed in the current study, we hypothesise that Ca2+ levels may regulate HDAC activity 337 
through activation of upstream kinases such as Ca2+/Calmodulin dependent kinase (CaMK), 338 
protein kinase D (PKD) and Aurora A kinase-dependent (AURKA) [27-29, 52-55]. Studies 339 
suggest TRPV4 stimulation with GSK101 promotes ERK/MAPK signalling in lung epithelial 340 
cells and cancer cells [56] and PKC activity in endothelial cells [57] which phosphorylate 341 
HDAC6 resulting in increased deacetylation activity [58, 59]. Indeed, increased HDAC6 342 
activity was observed in response to GSK101 (Fig. 4D). 343 
In conclusion, this study demonstrates a role for TRPV4 activation in the anti-inflammatory 344 
mechanism of loading. In addition to providing new mechanistic understanding of this 345 
pathway, this study identifies TRPV4 as a potential therapeutic target and demonstrates that 346 
pharmaceutical activation of this protein could regulate inflammation and other IFT-347 
dependent pathways involved in cartilage disease. 348 
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